Neurology Information Center
Research findings from Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 provide updates on MS diagnosis and treatment.
News
Health awareness campaigns occur all throughout the year in a wide variety of medical fields. These are when health awareness days, weeks, and months are happening this year.
News, Stat Consult
This review provides a concise overview of the types, pathogenesis, diagnostic criteria, differential diagnosis, and treatment of multiple sclerosis.
Pediatrics Information Center
Gilenya is the first multiple sclerosis drug approved for children
Web Exclusives
Dimethyl fumarate is the third oral medication available to treat multiple sclerosis.
Neurology Information Center
The FDA approved Ocrevus to treat adults with primary progressive multiple sclerosis and relapsing forms of the disease.
Web Exclusives
Patients with multiple sclerosis who had high levels of sodium intake were 3.4 times more likely to develop a new lesion.
Evidence-Based Medicine
Level 3: Lacking direct evidence Dalfampridine (Ampyra) extended release tablets, previously called Fampridine-SR, have been approved by the FDA to improve walking in patients with multiple sclerosis. In two clinical trials with 507 patients, the drug was associated with consistent improvement in walking speed on a 25-foot walk when compared with placebo (NNT 4). However,…
Neurology Information Center
Investigators assessed a large population of Italian patients with resistant multiple sclerosis spasticity treated with THC:CBD to determine real-life, long-term efficacy outcomes.
Neurology Information Center, News
MS patients advised to follow all local vaccine standards except in case of specific contraindications.
